The Use of Ketamine to Treat Suicidal Ideation by Smith, Angelia C
Pacific University 
CommonKnowledge 
School of Physician Assistant Studies College of Health Professions 
Summer 8-12-2017 
The Use of Ketamine to Treat Suicidal Ideation 
Angelia C. Smith 
Pacific University 
Recommended Citation 
Smith, Angelia C., "The Use of Ketamine to Treat Suicidal Ideation" (2017). School of Physician Assistant 
Studies. 617. 
https://commons.pacificu.edu/pa/617 
This Capstone Project is brought to you for free and open access by the College of Health Professions at 
CommonKnowledge. It has been accepted for inclusion in School of Physician Assistant Studies by an authorized 
administrator of CommonKnowledge. For more information, please contact CommonKnowledge@pacificu.edu. 
The Use of Ketamine to Treat Suicidal Ideation 
Abstract 
Background: Suicide is one of the leading causes of death in the United States. Research has shown that 
the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine can significantly decrease 
depressive symptoms, which is a leading cause of suicidal ideation (SI). Preliminary research has shown 
that ketamine effectively reduces SI. The purpose of this systematic review is to expand on the current 
understanding of ketamine as a way to treat SI. 
Methods: An exhaustive search of available medical literature was preformed using OVID, Google Scholar 
and Web of Science. Keywords included suicide and ketamine. Quality of the eligible studies were 
evaluated using the Cochrane GRADE method. 
Results: Two articles met the eligibility criteria for this review. One study was a randomized controlled trial 
(RCT) that evaluated the efficacy between ketamine and midazolam on the treatment of SI in adults with 
mood and anxiety spectrum disorders. Findings of this study showed that IV ketamine was superior to a 
single dose of midazolam 48-hours post-infusion. The second study was a secondary analysis of an 
open-label study that evaluated the effects of ketamine on SI in patients with major depressive disorder 
(MDD). Findings of this study showed that repeated IV infusions of ketamine rapidly reduced suicidal 
ideation and intensity 4 hours-post infusion with lasting long-term effects in some patients. 
Conclusion: The current findings provide support for the use of ketamine to reduce SI. Further research is 
needed to evaluate treatment duration, long-term side effects, alternative administration routes, and 
isolated effects of ketamine on SI. 
Keywords: Ketamine, depression, suicide, ideation, prevention 
Degree Type 
Capstone Project 
Degree Name 
Master of Science in Physician Assistant Studies 
Keywords 
Ketamine, depression, suicide, ideation, prevention 
Subject Categories 
Medicine and Health Sciences 
This capstone project is available at CommonKnowledge: https://commons.pacificu.edu/pa/617 
Copyright and terms of use 
If you have downloaded this document directly from the web or from CommonKnowledge, see 
the “Rights” section on the previous page for the terms of use. 
If you have received this document through an interlibrary loan/document delivery service, the 
following terms of use apply: 
Copyright in this work is held by the author(s). You may download or print any portion of this 
document for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). 
Except for personal or fair use, you or your borrowing library may not reproduce, remix, 
republish, post, transmit, or distribute this document, or any portion thereof, without the 
permission of the copyright owner. [Note: If this document is licensed under a Creative 
Commons license (see “Rights” on the previous page) which allows broader usage rights, your 
use is governed by the terms of that license.] 
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge 
Rights, Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. 
Email inquiries may be directed to:.copyright@pacificu.edu 
- 1 -
The Use of Ketamine to Treat Suicidal Ideation 
Angelia Smith 
A Clinical Graduate Project Submitted to the Faculty of the 
School of Physician Assistant Studies 
Pacific University 
Hillsboro, OR 
For the Masters of Science Degree, 2017 
Clinical Graduate Project Coordinator: Annjanette Sommers, PA-C, MS 
- 2 -
Biography 
[Redacted for privacy]
- 3 -
Abstract 
Background: Suicide is one of the leading causes of death in the 
United States. Research has shown that the glutamate N-methyl-D-
aspartate (NMDA) receptor antagonist ketamine can significantly 
decrease depressive symptoms, which is a leading cause of suicidal 
ideation (SI). Preliminary research has shown that ketamine effectively 
reduces SI. The purpose of this systematic review is to expand on the 
current understanding of ketamine as a way to treat SI. 
Methods: An exhaustive search of available medical literature was 
preformed using OVID, Google Scholar and Web of Science. Keywords 
included suicide and ketamine. Quality of the eligible studies were 
evaluated using the Cochrane GRADE method.  
Results: Two articles met the eligibility criteria for this review. One 
study was a randomized controlled trial (RCT) that evaluated the 
efficacy between ketamine and midazolam on the treatment of SI in 
adults with mood and anxiety spectrum disorders. Findings of this 
study showed that IV ketamine was superior to a single dose of 
midazolam 48-hours post-infusion. The second study was a secondary 
analysis of an open-label study that evaluated the effects of ketamine 
on SI in patients with major depressive disorder (MDD). Findings of 
this study showed that repeated IV infusions of ketamine rapidly 
reduced suicidal ideation and intensity 4 hours-post infusion with 
lasting long-term effects in some patients. 
Conclusion: The current findings provide support for the use of 
ketamine to reduce SI. Further research is needed to evaluate 
treatment duration, long-term side effects, alternative administration 
routes, and isolated effects of ketamine on SI.    
Keywords:   Ketamine, depression, suicide, ideation, prevention 
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The Use of Ketamine to Treat Suicidal Ideation 
BACKGROUND 
In the United States (US) suicide is considered to be one of the leading causes of 
death. Statistics from the Center for Disease Control (CDC) show that there were 41 149 
suicides in 2013 ranking it as the tenth leading cause of death.1 The rate of suicide has 
increased 24% within the last 15 years making it a serious public health concern.2 The 
rates in minorities such as American Indians, Alaska Natives, Pacific Islanders and those 
reporting multiple ethnic backgrounds are even higher than the average.3 The CDC has 
also reported that nearly 494 000 of those in the US receive emergency medical care for 
self-inflicted injuries, resulting in a 10.4 billion cost.1  
To reduce the rate of suicide it has been suggested by the CDC to use a 4-step 
approach.4 The 4 steps include defining the problem, identifying the factors contributing 
to suicide, implementing prevention strategies and ensuring widespread adoption. 
Defining the problem will require exhaustive collection of past and present data regarding 
completed suicides, suicide attempts and suicidal ideation (SI). Data showing who is at 
higher risk will help target preventative efforts.  
Next, identifying risk factors and prevention factors will play an integral role as to 
why suicide has become such a large public health concern. Already established risk 
factors include a history of mental illness, substance abuse, previous suicide attempts, 
family history of suicide attempts, physical illness, feelings of being alone and being 
male (although females are reported to have more frequent suicidal ideation). Research5 
on the psychological autopsy studies of suicide suggest that the most effective suicide 
prevention strategies should focus on the treatment of mental disorders specifically. This 
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is primarily suggested because mental disorders such as major depressive disorder 
(MDD) had the strongest associations with suicide when compared to a variety of other 
factors.   
Decreasing risk factors of suicide, education of the warning signs of suicide and the 
promotion of patient protective factors may act as prevention strategies. Currently, 
suicide prevention focuses on the treatment of MDD which the DSM-V classifies as a 
depressive disorder.6 Depressive disorders vary but are all characterized by feelings of 
sadness, emptiness, irritability and a decreased capacity to function.   
In 2012, a review of research7 concluded that the glutamate N-methyl-D-aspartate 
(NMDA) receptor antagonist ketamine has been shown to significantly decrease 
depressive symptoms in adults with MDD. The ongoing research on ketamine’s effect on 
depression has led specifically to the study of ketamine and its effect on suicidal ideation 
(SI). Preliminary research8 published in February 2015 has shown that ketamine 
effectively reduces SI. The purpose of this systematic review is to expand on the current 
understanding of ketamine as a way to treat SI. If this additional research supports 
previous findings, this review may help ensure widespread adoption of this technique to 
decrease suicide risk.  
METHODS 
A comprehensive search of literature was performed using MEDLINE-Ovid, 
Google Scholar and Web of Science. The searched keywords included “suicide” and 
“ketamine”. The abstracts from articles published between 2015 to present were 
evaluated for inclusion. Studies were required to focus on the effects of ketamine on 
suicidal ideation. Additional inclusion criteria required articles to be published in the 
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English language and for the studies to be conducted on human subjects. Articles that met 
the inclusion criteria were evaluated using the GRADE method.9 This method assesses 
the design, limitations, inconsistency, indirectness, imprecision and publication bias of 
each study. 
RESULTS 
A total of 88 articles were reviewed for relevancy. Following the examination of 
the article’s titles and abstracts, two studies10,11 met the eligibility criteria for this review. 
The first study10 was a randomized controlled trial (RCT) examining the use of ketamine 
to reduce SI in adults with mood and anxiety spectrum disorders. The second study11 was 
an open-label secondary analysis focusing on the use of ketamine to reduce SI in adults 
with MDD. See Table 1. 
Murrough et al 
This randomized controlled trial10sought to evaluate the effects of ketamine on 
clinically significant SI. Patients were recruited through both an inpatient psychiatric 
service and an academic outpatient psychiatric clinic. Men and women between the ages 
of 18 and 80 years old were admitted to the study upon obtaining a Montgomery-Asberg 
Depression Rating Scale (MADRS-SI) of ≥4. A Columbia Suicide Severity Scale (C-
SSRS) score of ≥4 lead to the exclusion of outpatients. This was due to the correlation of 
this score with a high intent to commit suicide. Co-morbidities were screened by using 
the MINI interview. Patients were excluded for having a lifetime history of primary 
psychotic disorders, recent substance abuse, history of ketamine abuse, unstable medical 
illness or current psychotic or manic symptoms.10  
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 Twenty-four patients were randomized into a ketamine group or midazolam 
group. Before the initiation of treatment, each participant underwent baseline screening to 
assess SI severity. After screening they received either 0.5mg/kg of racemic ketamine 
hydrochloride or 0.045mg/kg of midazolam using a double-blind technique. Each 
participant was evaluated at 24, 48, 72 hours and finally at 7 days after receiving 
treatment.10  
The primary outcome of SI was measured with the 21-item self-report Beck Scale 
for Suicidal Ideation (BSI) with scores ranging from 0-42. Suicidality was also measured 
using the MADRS-SI with scores ranging from 0-6. A MADRS-SI score of 4 indicated 
moderate SI without a specific plan of harm and a score of 6 indicated active intention of 
committing suicide. Additional secondary outcomes included depression severity 
evaluated with MADRS and the Quick Inventory of Depressive Symptomatology-Self 
Report (QIDS-SR). Symptoms of SI were measured using the Concise Associated 
Symptoms Tracking (CAST) scale. Tools such as the Brief Psychiatric Rating Scale 
(BPRS), The Clinician-Administered Dissociative States Scale (CADSS) and the Patient 
Rated Inventory of Side Effects (PRISE) were utilized to monitor patient safety and 
tolerability of treatment.10  
At the 24, 72-hour and 7-day evaluations the BSI score differences between the 
ketamine and midazolam groups were not clinically significant. At the 48-hour 
evaluation, however, a significant difference between the 2 groups emerged (8.8±8.3 
ketamine and 15.3 ±10.9 midazolam) suggesting a greater decline in SI for the ketamine 
group. When evaluating MADRS-SI scores it was shown that those receiving ketamine 
had a significantly lower rating 24 hours post-treatment when compared to the 
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midazolam group (1.8±1.9 ketamine and 3.3±1.6 midazolam). General depression levels 
did not vary significantly.10  Additional secondary outcomes can be seen in Table 2. 
Undesired side effects of treatment emerged throughout the study. Some of the 
participants receiving ketamine reported transient dissociation, headaches, dizziness, 
anxiety, poor concentration, poor coordination and restlessness. Those receiving 
midazolam reported headache, dizziness, nausea/vomiting, diarrhea and anxiety. Both 
treatment groups had reports of acute psychotomimetic effects or mood elevation. 
Limitations noted in this study included a relatively small sample size.10 
Ionescu et al 
 This secondary analysis11 of an open-label study sought to evaluate the ability of 
ketamine to reduce thoughts of suicide in patients with treatment-resistant depression and 
current SI. Patients between the ages of 18-65 were recruited and screened at 
Massachusetts General Hospital. Inclusion criteria included meeting the DSM-IV criteria 
for MDD, plus scoring a ≥20 on the Hamilton Depression Rating Scale (HDRS). 
Treatment-resistant depression was defined as ≥3 failed treatment attempts of the current 
depressive episode. The study’s participants were all prescribed antidepressant 
medications for ≥4 weeks prior to the administration of ketamine. Participants were 
withdrawn from the study in the event of requiring antidepressant dose changes. The 
CADSS was utilized in baseline testing, 60 minutes and 120 minutes post-infusion to 
evaluate for adverse side effects. Outcomes throughout the life of the study were 
measured using the HDRS and C-SSRS scales. In addition to explicit outcome, implicit 
measures of SI were measured using the death/suicide Implicit Association Test (IAT) 
which measures response times of automatic mental association about specific topics.11 
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 Fourteen patients were enrolled into the study, 12 of which received all 6 
infusions of ketamine. Loss of participants was attributed to intolerable side effects and 
scheduling difficulties. Before the initiation of treatment, each participant underwent 3 
cycles of pretreatment screening to ensure they met the inclusion criteria and to evaluate 
the baseline data. After screening they received 2 ketamine infusions per week for a total 
of 3 weeks. The first 3 infusions were 0.5mg/kg, followed by 0.75mg/kg for the last 3 
infusions. Participants were routinely evaluated before, during and after the treatment. 
Post-treatment evaluations occurred every 2 weeks for 3 months.11  
 Acute treatment phase results showed that explicit SI measured by C-SSRS 
ideation scores decreased significantly. These scores decreased by an average of -0.27 per 
patient after each infusion. To isolate reduction of SI, the HDRS core depression items 
were controlled for yielding a coefficient of -0.12 implying that -0.12 of the -0.27 
decrease was a reduction in SI specifically. The change in dosage showed no significant 
effects. In addition to the C-SSRS ideation scores, the C-SSRS intensity scores were 
shown to decrease as well; however, these scores were not significant when compared 
individually. C-SSRS intensity scores were not influenced significantly by dose. Acute 
treatment phase results also showed that there was a significant reduction in implicit SI. 
The change in IAT scores yielded a coefficient of +0.05, suggesting that patients 
responded faster to words associated with death/suicide. The IAT scores were no longer 
significant after controlling for HDRS core depression items.11 
There were 11 patients who completed the follow-up phase. Seven of these 
patients achieved remission (HDRS <7) after the acute treatment phase and 2 of these 
patients continued this remission through the end of the follow-up phase. This suggests 
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that reduction in SI is maintainable for some. Limitations of this study included a 
relatively small sample size, lack of a blind experimental design and the absence of a 
control group.11   
DISCUSSION 
Since its development in 1962 as an anesthetic, ketamine has been established as 
having a variety of clinical uses. In addition to its anesthetic use, ketamine is now 
considered to be a pain-manager, anti-inflammatory and anti-depressant when 
administered in sub-anesthetic dosages.12 Between 2009-2012, data has shown that the 
prevalence of depression in Americans ≥12 years of age is 7.6%.13 Since patient well-
being encompasses mental as well as physical health, one could see how the utilization of 
ketamine as an anti-depressant and agent to reduce SI is significant in improving general 
health outcomes.   
In the two reviewed studies,10,11 a decrease in SI was significant following the 
infusion of ketamine. In the RCT10 it was shown that a single dose of IV ketamine was 
superior to a single dose of midazolam. A significant reduction in SI was apparent 48-
hours post-infusion, but this significance vanished in the longer term samples. Until this 
point, prior research8 has mainly focused on ketamine’s ability to reduce SI in those with 
depressive disorders such as MDD. However, the participants of this study had differing 
co-occurring mood and anxiety spectrum disorders which supports the finding that 
ketamine is useful in treating SI in a larger demographic. It was suggested by the authors 
of the RCT study10 that more research is needed to further separate the isolated effects of 
ketamine on SI independent of co-occurring disorders.   
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In the secondary analysis11 of an open-label study it was shown that repeated IV 
infusions of ketamine rapidly reduced suicidal ideation and intensity. This reduction in SI 
occurred 4 hours post-infusion. There was, however, a lack of significance of isolated 
intensity reduction of SI when depression core items were controlled for. In contrast to 
the RCT study10 it was found in the secondary analysis11 that ketamine has the ability to 
provide long-term remission of SI. While discussing the increase in death/suicide IAT 
scores regarding implicit SI, the authors of this study suggested that the resulting scores 
were difficult to interpret. This was attributed to the small sample size and the 
participant’s dislike of participating in the implicit measures of SI versus the explicit 
ones. The authors then suggested that a larger more controlled study is needed to study 
ketamine’s anti-suicidal effects.  
The quality assessment of the two reviewed studies10,11 can be seen in Table 1. An 
important limitation of these studies was the relatively small sample size. Having a small 
sample size can lead to the skewing of results which in turn can lead to inaccurate data. 
Due to this, the RCT10 was downgraded to a “moderate” quality. To increase study 
precision and overall quality of future studies a larger sample size should be 
considered.  Other importation limitations of secondary analysis11 was the lack of 
collector and participant blinding. This shortcoming in conjunction with the small sample 
size leads this study to be considered “very low” quality. However, research on this topic 
is in the beginning stages, thus explaining the lower quality of these studies. Through 
study refinement the limitations should diminish, leading to more accurate and reliable 
results.   
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CONCLUSION 
Current standard of care is to treat depression and SI with anti-depressants such as 
selective serotonin reuptake inhibitors (SSRIs) which are notorious for taking weeks 
before symptom resolution is established. In comparison, this systematic review provides 
evidence that ketamine more rapidly treats both depression and SI which may lead to 
improved patient outcomes. The results of this systematic review in conjunction with the 
prior systematic review are suggestive that the new and possibly more efficient treatment 
of SI with ketamine could become standard practice. Further research is needed to 
explore the potential of ketamine to rapidly and efficiently reduce SI both short and long-
term. Within this, the long-term side effects and isolated effects of ketamine on SI should 
be further evaluated. Although IV ketamine was utilized in both of the reviewed studies it 
may be beneficial to study less invasive routes of administration such as intranasal.  The 
intranasal administration of ketamine could be easily utilized in an outpatient setting 
while still allowing for rapid administration, thus reducing the cost of administration. 
This in itself could be integral in ensuring widespread prevention of suicide by the use of 
ketamine.  
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Table 1: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Morrough et 
al10 
RCT Not 
Serious 
Not Serious Not Serious Seriousa Unlikely none Moderate 
Ionescu et 
al11 
Secondary 
analysis 
Seriousb,c Not Serious Not Serious Seriousa Unlikely none Very low 
a Small sample size 
b Lack of blinding of data collectors and participants in the Ionescu et al study11  
c No control group in the Ionescu et al study11  
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Table 2: Effects of ketamine compared to midazolam on secondary outcomes in 
participants with clinically significant suicidal ideation10 
 
